glp-1 news past 2 days Alarming rise in weight loss drug overdoses Medicare GLP-1 access raises questions

T., Freeman, E

Lippincott Williams & Wilkins, Philadelphia, PA, USA Krishnan A, Hadi Y, Alqahtani SA et al (2023) Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity

Pipeline and Technology Innovation Analysis GLP-1 Weight Loss Drug Market Pipeline: Triple Agonists, Oral Formulations, and Amylin Combinations Define the 20262035 Innovation Frontier Key GLP-1 Pipeline Molecules, Mechanisms, Development Stage, and Peak Sales Projections Triple agonist therapies targeting GLP-1, GIP, and glucagon receptors simultaneously represent the most significant efficacy advance in obesity pharmacotherapy since semaglutide

This is the landscape were in right now